324 related articles for article (PubMed ID: 21484092)
1. Pharmacochemistry of the platelet purinergic receptors.
Jacobson KA; Deflorian F; Mishra S; Costanzi S
Purinergic Signal; 2011 Sep; 7(3):305-24. PubMed ID: 21484092
[TBL] [Abstract][Full Text] [Related]
2. Medicinal chemistry of adenosine, P2Y and P2X receptors.
Jacobson KA; Müller CE
Neuropharmacology; 2016 May; 104():31-49. PubMed ID: 26686393
[TBL] [Abstract][Full Text] [Related]
3. Molecular recognition at adenine nucleotide (P2) receptors in platelets.
Jacobson KA; Mamedova L; Joshi BV; Besada P; Costanzi S
Semin Thromb Hemost; 2005 Apr; 31(2):205-16. PubMed ID: 15852224
[TBL] [Abstract][Full Text] [Related]
4. Molecular recognition at purine and pyrimidine nucleotide (P2) receptors.
Jacobson KA; Costanzi S; Ohno M; Joshi BV; Besada P; Xu B; Tchilibon S
Curr Top Med Chem; 2004; 4(8):805-19. PubMed ID: 15078212
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes.
von Kügelgen I
Pharmacol Ther; 2006 Jun; 110(3):415-32. PubMed ID: 16257449
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of P2Y receptor subtypes - an update.
von Kügelgen I
Purinergic Signal; 2024 Apr; 20(2):99-108. PubMed ID: 37697211
[TBL] [Abstract][Full Text] [Related]
7. Molecular pharmacology of P2Y receptor subtypes.
von Kügelgen I
Biochem Pharmacol; 2021 May; 187():114361. PubMed ID: 33309519
[TBL] [Abstract][Full Text] [Related]
8. Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor.
Houston D; Costanzi S; Jacobson KA; Harden TK
Comb Chem High Throughput Screen; 2008 Jul; 11(6):410-9. PubMed ID: 18673269
[TBL] [Abstract][Full Text] [Related]
9. The P2Y/P2X divide: How it began.
Kennedy C
Biochem Pharmacol; 2021 May; 187():114408. PubMed ID: 33444568
[TBL] [Abstract][Full Text] [Related]
10. Purinoceptors: are there families of P2X and P2Y purinoceptors?
Abbracchio MP; Burnstock G
Pharmacol Ther; 1994; 64(3):445-75. PubMed ID: 7724657
[TBL] [Abstract][Full Text] [Related]
11. The P2 receptors and congenital platelet function defects.
Cattaneo M
Semin Thromb Hemost; 2005 Apr; 31(2):168-73. PubMed ID: 15852220
[TBL] [Abstract][Full Text] [Related]
12. Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.
Jacobson KA
J Med Chem; 2013 May; 56(10):3749-67. PubMed ID: 23597047
[TBL] [Abstract][Full Text] [Related]
13. The C6-2B glioma cell P2Y(AC) receptor is pharmacologically and molecularly identical to the platelet P2Y(12) receptor.
Jin J; Tomlinson W; Kirk IP; Kim YB; Humphries RG; Kunapuli SP
Br J Pharmacol; 2001 Jun; 133(4):521-8. PubMed ID: 11399669
[TBL] [Abstract][Full Text] [Related]
14. Agonists and antagonists for P2 receptors.
Jacobson KA; Costanzi S; Joshi BV; Besada P; Shin DH; Ko H; Ivanov AA; Mamedova L
Novartis Found Symp; 2006; 276():58-68; discussion 68-72, 107-12, 275-81. PubMed ID: 16805423
[TBL] [Abstract][Full Text] [Related]
15. Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets.
Jagroop IA; Burnstock G; Mikhailidis DP
Platelets; 2003 Feb; 14(1):15-20. PubMed ID: 12623443
[TBL] [Abstract][Full Text] [Related]
16. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors.
Chang H; Yanachkov IB; Michelson AD; Li Y; Barnard MR; Wright GE; Frelinger AL
Thromb Res; 2010 Feb; 125(2):159-65. PubMed ID: 19945153
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and structure of P2Y receptors.
von Kügelgen I; Hoffmann K
Neuropharmacology; 2016 May; 104():50-61. PubMed ID: 26519900
[TBL] [Abstract][Full Text] [Related]
18. The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: The role of p2x receptors.
Orriss IR; Key ML; Brandao-Burch A; Patel JJ; Burnstock G; Arnett TR
Bone; 2012 Sep; 51(3):389-400. PubMed ID: 22749889
[TBL] [Abstract][Full Text] [Related]
19. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
